Understanding the Diagnosis
Produced in collaboration with ILD Collaborative
Support for this patient education program was provided by Genentech.
Idiopathic Pulmonary Fibrosis (IPF) is a rare form of interstitial lung disease that causes scarring of the lungs for an unknown reason. While the root cause of the condition is not yet well understood, patients are being diagnosed and there are treatment options available.
Join us for a free, live video education program that helps patients and caregivers better understand:
- Diagnosis: signs and symptoms of the disease, what tests are involved, receiving a second opinion, genetics of IPF
- Treatment: what choices are available, what side effects may occur, slowing disease progression, committing to treatment
- Supportive Care: supplemental oxygen, pulmonary rehabilitation, palliative care, patient and caregiver support groups
Produced in collaboration with the ILD Collaborative – a clinical care and research network specializing in interstitial lung disease – this program provides important information to those newly diagnosed with IPF and those already in treatment.
Register to attend the program live or receive a recording via email.
Peter P. LaCamera, MD
St. Elizabeth’s Medical Center
Peter P. LaCamera, MD, is Chief, Division of Pulmonary, Critical Care & Sleep Medicine, and the director of the Interstitial Lung Disease Program at St. Elizabeth’s Medical Center in Boston, Massachusetts. Prior to joining St. Elizabeth’s Medical Center, he was a member of the pulmonary and critical care staff at Beth Israel Deaconess Medical Center in Boston, and co-director of its Interstitial Lung Disease Center. Dr LaCamera has participated in numerous clinical trials investigating new therapies for IPF, and is currently the medical director of the ILD Collaborative, an organization composed of patients and physicians working together to advance interstitial lung disease knowledge and care. He received his medical degree from the University of Massachusetts Medical School in Worcester.
Katharine E. Black, MD
Massachusetts General Hospital
Dr. Katharine Black is a pulmonologist at the Massachusetts General Hospital (MGH) Interstitial Lung Disease (ILD) Program. She is a physician and research scientist in the MGH Division of Pulmonary and Critical Care Medicine, and an Instructor in Medicine at Harvard Medical School. Dr. Black’s clinical activities focus on patients with fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF) and connective tissue-associated ILD; she also follows hospitalized patients who have undergone a lung transplant. Dr. Black is currently not seeing new clinic patients, as she is focusing on research in the fibrotic lung diseases. Working in the research laboratory of Dr. Andrew Tager, she investigates the mechanisms through which IPF, scleroderma and other fibrotic diseases develop and progress. Her main focus is on the interaction between the epithelial cells that normally line the lung and the fibroblasts that lay down extracellular matrix leading to fibrosis. Current understanding of pulmonary fibrosis suggests that injury to the epithelial cells sends signals that drive the increase in fibroblast numbers, and the increase in the scar tissue that these cells form, that characterize pulmonary fibrosis. Using patient samples as much as possible, Dr. Black is working to identify these signals, with the goal of devising treatments to block them and thereby prevent fibrosis progression.
Jess R. Garton, PT, DPT, OCS, CLT
Massachusetts General Hospital
Jessica Riggs Garton, PT, DPT, OCS, CLT, is a physical therapist at Massachusetts General Hospital (MGH) in Boston and works as part of the multidisciplinary pulmonary rehabilitation team. Dr Garton believes in the benefits of exercise and works with patients with lung disease to help them improve their endurance, overall function, and quality of life. She has been employed at MGH for over 10 years, where she has been recognized as an advanced clinician. She has presented on the benefits of pulmonary rehabilitation at the Interstitial Lung Disease Program at MGH and at the ILD Symposium. Dr Garton earned her bachelor of science in computer engineering from Brown University in Providence, Rhode Island, and a doctorate of physical therapy from MGH Institute of Health Professions.
Judy Amendola is an IPF patient living in Cambridge, Massachusetts and part time in New Orleans, Louisiana. She recently retired from work as family liaison and graphic designer. She was diagnosed with IPF in April of 2013. Her particular disease likely stems from an inherited genetic predisposition. In addition to her professional experience, Judy has gained insights from her experiences with IPF and the illnesses of several different family members. They include multiple myeloma with autologous stem cell transplant, severe adult rheumatoid arthritis with extended rehab, IPF, surgery & extended rehab for aortal aneurism, surgery & extended rehab relative to aortal stent at the bifurcation, extended geriatric care in a nursing home setting, as well as several diseases secondary to those mentioned. She is eager to share her insights relative to IPF.